Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Nintedanib is a small molecule tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR). The purpose of the study was to evaluate the response rate for patients with advanced non-small cell lung cancer (NSCLC) with mutations in , , , , and treated with nintedanib as part of an open-label, single-arm pilot study.
Methods: Patients with advanced NSCLC previously treated with platinum-doublet chemotherapy with the above mutations were enrolled. Exclusion criteria included necrotic tumors with invasion of blood vessels, history of recent thromboembolic events, increased risk of bleeding or thrombosis, myocardial infarction, and weight loss >10% within past 6 months. Nintedanib was administered at a dose of 200 mg orally twice daily until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Secondary endpoints included progression-free survival (PFS) and correlating outcomes with specific mutations. This study was registered with ClinicalTrials.gov, number NCT02299141.
Results: Between 2015 and 2019, 20 patients were enrolled with a median age was 66 years, 15 (75%) were females, 15 (75%) had adenocarcinoma, and 17 patients had a mutation (85%). Seventeen (85%) had received prior immunotherapy and 11 (55%) had received at least three prior lines of systemic therapy. The ORR was 15% with three partial responses (PR), while 12 patients had stable disease (SD), with disease control rate (DCR) consisting of a PR and SD greater than or equal to 16 weeks of 65% (n=13). Median PFS was 4.3 months [95% confidence interval (CI): 1.8-7.9] and median overall survival (OS) was 11.3 months (95% CI: 3.5-44.2). Three patients experienced prolonged clinical benefit from nintedanib, remaining on treatment for over 1 year and all three had a mutation and received prior immunotherapy. The most common adverse events of any grade included nausea (80%), fatigue (70%), diarrhea (60%), and anorexia (60%).
Conclusions: In this pilot study in heavily pretreated and molecularly selected patients with metastatic NSCLC, nintedanib showed modest activity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11228753 | PMC |
| http://dx.doi.org/10.21037/jtd-23-1717 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The effects of missing data due to study dropout on longitudinal analysis inference using outcome-dependent sampling.
Int J Epidemiol
August 2025
Department of Biostatistics and Informatics, University of Colorado, Aurora, CO, United States.
Background: Existing longitudinal cohort study data and associated biospecimen libraries provide abundant opportunities to efficiently examine new hypotheses through retrospective specimen testing. Outcome-dependent sampling (ODS) methods offer a powerful alternative to random sampling when testing all available specimens is not feasible or biospecimen preservation is desired. For repeated binary outcomes, a common ODS approach is to extend the case-control framework to the longitudinal setting.
View Article and Find Full Text PDFPrinciples of Industry-Academic Partnerships Informed by Digital Mental Health Collaboration: Mixed Methods Study.
JMIR Ment Health
September 2025
National Institute of Health and Care Research MindTech HealthTech Research Centre, School of Medicine, University of Nottingham, Nottingham, United Kingdom.
Background: Cross-sector collaboration is increasingly recognized as essential for addressing complex health challenges, including those in mental health. Industry-academic partnerships play a vital role in advancing research and developing health solutions, yet differing priorities and perspectives can make collaboration complex.
Objective: This study aimed to identify key principles to support effective industry-academic partnerships, from the perspective of industry partners, and develop this into actionable guidance, which can be applied across sectors.
Key factors underpinning neuroimmune-metabolic-oxidative (NIMETOX) major depression in outpatients: paraoxonase 1 activity, reverse cholesterol transport, increased atherogenicity, protein oxidation, and differently expressed cytokine networks.
Neuro Endocrinol Lett
September 2025
Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
Background: Major depressive disorder (MDD) is associated with neuro-immune - metabolic - oxidative (NIMETOX) pathways.
Aims: To examine the connections among NIMETOX pathways in outpatient MDD (OMDD) with and without metabolic syndrome (MetS); and to determine the prevalence of NIMETOX aberrations in a cohort of OMDD patients.
Methods: We included 67 healthy controls and 66 OMDD patients and we assessed various NIMETOX pathways.
Evaluation of nutritional status and swallowing functions of children with neuromuscular disordes.
Neuro Endocrinol Lett
September 2025
Department of Pediatric Neurology, Cukurova University Faculty of Medicine, Adana, Turkey.
Objective: It is important to raise awareness of the nutritional problems that can be overlooked during the follow-up visits with children who suffer from neuromuscular diseases, as these dietary differences may lead to additional neurological and systemic problems and impair the quality of life of the patient. The aim of this study was to evaluate the nutritional status of children with neuromuscular disorders and to prevent possible complications by recognizing possible nutritional problems in advance.
Methods: Patients who applied to the outpatient clinic at Cukurova University, Faculty of Medicine, Department of Pediatric Neurology beginning in April 2022 with a neuromuscular disorder diagnosis were followed up with and were included in the study.
Health Inequity in People with Cystic Fibrosis: Can We Close the Gap?
Ann Am Thorac Soc
September 2025
Hadassah Medical Center, Pediatric Pulmonology Unit and Cystic Fibrosis Center, Jerusalem, Jerusalem, Israel.
Background Although advances in care have improved cystic fibrosis (CF) outcomes in higher-income countries (HICs), the situation remains alarming in lower-income countries (LICs). Methods People with CF (pwCF) enrolled in the European Cystic Fibrosis Society Patient Registry (ECFSPR) and carrying at least one F508del variant allele were evaluated in 2017 and in 2022 for predicted percent forced expiratory volume (ppFEV1), underweight status, and chronic Pseudomonas aeruginosa (Pa) infection, according to the gross national income (GNI) per capita divided into three terciles (low-income countries, LICs; middle-income countries, MICs; and high-income countries, HICs). Survival was evaluated in the periods 2013-2017 and 2018-2022.
View Article and Find Full Text PDF